CoChat

The 10-Year Cost-Effectiveness of Lifestyle Intervention or Metformin for Diabetes Prevention

Open access
The Diabetes Prevention Program Research Group · 2012 · Diabetes Care

The DOI matches its Crossref record, with a small difference in title or year; 22 of the 22 references it cites were found in a registry or an index.

Abstract

OBJECTIVE: The Diabetes Prevention Program (DPP) and its Outcomes Study (DPPOS) demonstrated that either intensive lifestyle intervention or metformin could prevent type 2 diabetes in high-risk adults for at least 10 years after randomization. We report the 10-year within-trial cost-effectiveness of the interventions. RESEARCH DESIGN AND METHODS: Data on resource utilization, cost, and quality of life were collected prospectively. Economic analyses were performed from health system and societal perspectives. RESULTS: Over 10 years, the cumulative, undiscounted per capita direct medical costs of the interventions, as implemented during the DPP, were greater for lifestyle ($4,572) than metformin ($2,281) or placebo ($752). The cumulative direct medical costs of care outside the DPP/DPPOS were least for lifestyle ($26,810 lifestyle vs. $27,384 metformin vs. $29,007 placebo). The cumulative, combined total direct medical costs were greatest for lifestyle and least for metformin ($31,382 lifestyle vs. $29,665 metformin vs. $29,759 placebo). The cumulative quality-adjusted life-years (QALYs) accrued over 10 years were greater for lifestyle (6.89) than metformin (6.79) or placebo (6.74). When costs and outcomes were discounted at 3% and adjusted for survival, lifestyle cost $12,878 per QALY, and metformin had slightly lower costs and nearly the same QALYs as placebo. CONCLUSIONS: Over 10 years, from a payer perspective, lifestyle was cost-effective and metformin was marginally cost-saving compared with placebo. Investment in lifestyle and metformin interventions for diabetes prevention in high-risk adults provides good value for the money spent.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.2337/dc11-1468

Cites

22 of 22 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 —A: Cumulative, undiscounted, per participant, direct medical costs of the DPP/DPPOS interventions by intervention group and study year. B: Cumulative, undiscounted, per participant, direct medical costs of medical care received outside the DPP/DPPOS by intervention group and study year. C: Cumulative, undiscounted, per participant, total direct medical costs of the DPP/DPPOS interventions and medical care received outside the DPP/DPPOS by intervention group and study year. D: Cumulative, undiscounted, per participant, total Quality of Well-Being Index by intervention group and year.
Figure 1 —A: Cumulative, undiscounted, per participant, direct medical costs of the DPP/DPPOS interventions by intervention group and study year. B: Cumulative, undiscounted, per participant, direct medical costs of medical care received outside the DPP/DPPOS by intervention group and study year. C: Cumulative, undiscounted, per participant, total direct medical costs of the DPP/DPPOS interventions and medical care received outside the DPP/DPPOS by intervention group and study year. D: Cumulative, undiscounted, per participant, total Quality of Well-Being Index by intervention group and year.CC BY-NC-ND · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 22 references

Cited by

See all 498

Metadata

Authors
The Diabetes Prevention Program Research Group
Affiliations
University of Michigan (US)
Corresponding author
The Diabetes Prevention Program Research Group
Venue
Diabetes Care
Published
2012-03-13
Volume
35
Issue
4
Pages
723-730
ISSN
  • 0149-5992 (ISSN-L)
  • 1935-5548
OpenAlex
W1896651021
Cited by
436
References
22
Citations by year
2026: 16 · 2025: 19 · 2024: 22 · 2023: 19 · 2022: 19 · 2021: 28 · 2020: 38 · 2019: 42 · 2018: 39 · 2017: 43 · 2016: 38 · 2015: 32 · 2014: 29 · 2013: 31 · 2012: 19
FWCI
84.94
Type
journal article
Language
en
Open access
Licence
cc-by-nc-nd
Locations
  • Diabetes Care (publishedVersion, cc-by-nc-nd)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by-nc-nd)
  • PubMed Central (publishedVersion, cc-by-nc-nd)
  • PubMed (publishedVersion)
Funders
  • National Institutes of Health
  • National Institute of Diabetes and Digestive and Kidney Diseases (P30DK092926, P30DK017047)
  • National Center for Research Resources
Topics
  • Social Sciences › Economics, Econometrics and Finance › Economics and Econometrics › Health Systems, Economic Evaluations, Quality of Life
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
Keywords
type 2 diabetes prevention, lifestyle intervention, metformin, cost-effectiveness, Diabetes Prevention Program Outcomes Study, quality-adjusted life years, high-risk adults, direct medical costs, resource utilization (health care), health system perspective, societal perspective
MeSH terms
Adult, Combined Modality Therapy, Cost-Benefit Analysis, Diabetes Mellitus, Type 2, Female, Follow-Up Studies, Humans, Hypoglycemic Agents, Male, Metformin, Middle Aged, Prediabetic State, Prognosis, Time Factors, Randomized Controlled Trials as Topic, Treatment Outcome, Risk Reduction Behavior, Intention to Treat Analysis

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: The 10-Year Cost-Effectiveness of Lifestyle Intervention or Metformin for Diabetes Prevention. https://app.cochat.ai/papers/10.2337/dc11-1468
The paper
The Diabetes Prevention Program Research Group. (2012). The 10-Year Cost-Effectiveness of Lifestyle Intervention or Metformin for Diabetes Prevention. Diabetes Care. https://doi.org/10.2337/dc11-1468

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.